The PSA doubling time estimates how quickly PSA is rising between two tests using an exponential growth model.
Enter up to 6 PSA test values (within a 12 month period; minimum 2 values) and their dates to see the estimated doubling time in days and months.
For clinical interpretation, formal methods typically use several PSA points, since reliability improves when at least three recent measurements are available.
References:
- D’Amico, A. V., Moul, J. W., Carroll, P. R., Sun, L., Lubeck, D., & Chen, M. H. (2003). Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. Journal of the National Cancer Institute, 95(18), 1376–1383.
- Khatami, A., Aus, G., Damber, J. E., Lilja, H., Lodding, P., & Hugosson, J. (2007). PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. International journal of cancer, 120(1), 170–174.
- Lee, A. K., Levy, L. B., Cheung, R., & Kuban, D. (2005). Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. International journal of radiation oncology, biology, physics, 63(2), 456–462.
- Markowski, M. C., Chen, Y., Feng, Z., Cullen, J., Trock, B. J., Suzman, D., Antonarakis, E. S., Paller, C. J., Rosner, I., Han, M., Walsh, P. C., Partin, A. W., & Eisenberger, M. (2019). PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical genitourinary cancer, 17(6), 470–475.e1.
- Spurgeon, S. E., Mongoue-Tchokote, S., Collins, L., Priest, R., Hsieh, Y. C., Peters, L. M., Beer, T. M., Mori, M., & Garzotto, M. (2007). Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy. Urology, 69(5), 931–935.
- Lu, H. H., Chiu, N. T., & Tsai, M. H. (2024). Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy. Annals of nuclear medicine, 38(7), 508–515.